Cimzia (certolizumab pegol) is a tumor necrosis factor (TNF) inhibitor, a type of biologic drug that reduces inflammation by targeting TNF-alpha, a key protein involved in the immune system’s inflammatory response. Overproduction of TNF-alpha contributes to the symptoms of several chronic autoimmune diseases.

FDA-approved uses include:

• Rheumatoid arthritis (RA)

• Psoriatic arthritis (PsA)

• Ankylosing spondylitis (AS)

• Non-radiographic axial spondyloarthritis

• Crohn’s disease

• Plaque psoriasis

How it works:

• Cimzia binds to TNF-alpha and neutralizes its activity.

• This helps reduce inflammation, pain, and damage to joints or the digestive tract, depending on the disease being treated.

Unique feature:

• Cimzia is pegylated (chemically linked to polyethylene glycol), which may allow for longer duration of action and less placental transfer—making it a potential option for use during pregnancy (with physician oversight).

Administration:

• Given as a subcutaneous injection, usually every 2 to 4 weeks after an initial loading dose.

• Available in prefilled syringes or autoinjector pens.

Common side effects:

• Injection site reactions

• Upper respiratory infections

• Headache

• Nausea

Serious risks:

• Increased risk of serious infections (e.g., tuberculosis)

• Risk of certain cancers

• Potential nervous system problems

• Allergic reactions

Before starting Cimzia, patients are usually screened for tuberculosis and other infections.